Evidence map›Paper›PMID 42239463›Full record

ArticlebioRxiv : the preprint server for biology2026

Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodies.

Cody Fell, Anthony E Davis, Shalini Pandey, Michael T Guinn, Zeshi Wang, Jonathon DeBonis, Chancellor Smith, Nathan Brown, Danna Murungi, Yeonju Kim and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Cody FellDepartment of Bioengineering, Rice University, Houston, TX, USA.
Anthony E DavisDepartment of Bioengineering, Rice University, Houston, TX, USA.
Shalini PandeyDepartment of Bioengineering, Rice University, Houston, TX, USA.
Michael T GuinnDepartment of Bioengineering, Rice University, Houston, TX, USA.
Zeshi WangDepartment of Bioengineering, Rice University, Houston, TX, USA.
Jonathon DeBonisDepartment of Bioengineering, Rice University, Houston, TX, USA.
Chancellor SmithDepartment of Bioengineering, Rice University, Houston, TX, USA.
Nathan BrownDepartment of Bioengineering, Rice University, Houston, TX, USA.
Danna MurungiDepartment of Bioengineering, Rice University, Houston, TX, USA.
Yeonju KimDepartment of Bioengineering, Rice University, Houston, TX, USA.
Imaan MohandessiDepartment of Bioengineering, Rice University, Houston, TX, USA.
Patrick BednarzDepartment of Bioengineering, Rice University, Houston, TX, USA.
Amir ArdeshirDivision of Microbiology, Tulane National Biomedical Research Center, Covington, LA, USA.
Erin M HauptDivision of Microbiology, Tulane National Biomedical Research Center, Covington, LA, USA.
Samuel I CuevasDivision of Microbiology, Tulane National Biomedical Research Center, Covington, LA, USA.
Christy L LavineCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA USA.
Oleg IgoshinDepartment of Bioengineering, Rice University, Houston, TX, USA.
Ravi K GhantaMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Michael R DiehlDepartment of Bioengineering, Rice University, Houston, TX, USA.
Omid VeisehDepartment of Bioengineering, Rice University, Houston, TX, USA.

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael T. Lewis · 2007 to 2026
$73.9M
CyTOF XT with Hyperion XTi platformS10OD036336 · OD · BAYLOR COLLEGE OF MEDICINE · PI BEETON, CHRISTINE · 2024 to 2024
$829k
BD FACSDiscover S8 Spectral and Imaging Cell SorterS10OD038251 · OD · BAYLOR COLLEGE OF MEDICINE · PI BEETON, CHRISTINE · 2025 to 2025
$563k
Bill & Melinda Gates Foundation INV-036842NCI NIH HHS P30 CA125123NIH HHS P51 OD011104NIH HHS S10 OD036336NIH HHS S10 OD038251
6 · The paper itself

Abstract

Over 200 monoclonal antibodies (mAbs) are approved for clinical use, yet their therapeutic potential is constrained by dependence on repeated injections or infusions that drive non-adherence, limit access in low-resource settings, and generate peak-trough pharmacokinetics linked to adverse effects and reduced efficacy. Here, we developed an immunomodulatory encapsulated cell-based 'biologics factory' that overcomes mAb instability, immunogenicity, and the fibrotic foreign body response that have limited previous approaches, enabling continuous

Identifiers

PMID42239463
PMCPMC13228534

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.